GGrantIndex
← Leaderboards

Katherine P. Ponder

Barnes-Jewish Hospital

$6,715,942
Attributed
$6,715,942
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $794.5K · FY200513
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$6,715,942 · 6

By mechanism

R01$6,202,951 · 4
R56$321,453 · 1
K02$191,538 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Gene Therapy

Research focus

Gene TherapyTransfection /Expression VectorLaboratory MouseLiver CellsRetroviridaeNewborn AnimalsDogsAntibody FormationLiverGene ExpressionEnzyme Linked Immunosorbent AssayAnimal ModelComplementary DnaMucopolysaccharidosis ILysosomal Storage DiseasesSymptomsOrganEnzyme Replacement TherapyPreventCanis FamiliarisGlycosaminoglycansEnzymesHematopoietic Stem Cell TransplantationProteins

Grant awards (28)

RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I$316,075
R01 · FY2013 · DK · contact PI
RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I$327,539
R01 · FY2012 · DK · contact PI
RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I$327,539
R01 · FY2011 · DK · contact PI
PATHOGENESIS OF DISEASE IN MUCOPOLYSACCHARIDOSIS I AND VII$383,998
R01 · FY2010 · HD · contact PI
RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I$365,072
R01 · FY2010 · DK · contact PI
PATHOGENESIS OF DISEASE IN MUCOPOLYSACCHARIDOSIS I AND VII$396,581
R01 · FY2009 · HD · contact PI
RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I$381,760
R01 · FY2009 · DK · contact PI
RETROVIRAL VECTOR-MEDIATED LIVER GENE THERAPY FOR MPS I$240,436
R56 · FY2008 · DK · contact PI
Retroviral Vector-Mediated Liver Gene Therapy for MPS I$81,017
R56 · FY2007 · DK · contact PI
Retroviral Vector-mediated Liver Gene Therapy for MPS I$286,480
R01 · FY2006 · DK · contact PI
Improved Methods for In Vivo Hepatic Gene Therapy$272,678
R01 · FY2006 · DK · contact PI
Improved Methods for In Vivo Hepatic Gene Therapy$279,240
R01 · FY2005 · DK
Gene Therapy for Blood Protein Deficiencies$264,431
R01 · FY2005 · DK
Retroviral Vector-mediated Liver Gene Therapy for MPS I$250,779
R01 · FY2005 · DK
Improved Methods for In Vivo Hepatic Gene Therapy$279,240
R01 · FY2004 · DK
Gene Therapy for Blood Protein Deficiencies$266,804
R01 · FY2004 · DK
Retroviral Vector-mediated Liver Gene Therapy for MPS I$262,195
R01 · FY2004 · DK
Improved Methods for In Vivo Hepatic Gene Therapy$279,240
R01 · FY2003 · DK
Retroviral Vector-mediated Liver Gene Therapy for MPS I$243,785
R01 · FY2003 · DK
Gene Therapy for Blood Protein Deficiencies$182,272
R01 · FY2003 · DK
Gene Therapy for Blood Protein Deficiencies$90,161
R01 · FY2003 · DK
Retroviral Vector-mediated Liver Gene Therapy for MPS I$6,739
R01 · FY2003 · DK
Improved Methods for In Vivo Hepatic Gene Therapy$219,952
R01 · FY2002 · DK
Gene Therapy for Blood Protein Deficiencies$197,981
R01 · FY2002 · DK
IMPROVED METHODS FOR IN VIVO HEPATIC GENE THERAPY$163,263
R01 · FY2001 · DK
HEPATIC GENE THERAPY USING RETROVIRAL VECTORS$95,891
K02 · FY2001 · DK
IMPROVED METHODS FOR IN VIVO HEPATIC GENE THERAPY$159,147
R01 · FY2000 · DK
HEPATIC GENE THERAPY USING RETROVIRAL VECTORS$95,647
K02 · FY2000 · DK